Olmesartan Medoxomil and Cilnidipine Tablet

OLMEROOT-CL 40

Olmesartan Medoxomil 40 mg and Cilnidipine 10 mg Tablets

Division: DIABGLYM

Composition

Each tablet contains:

Olmesartan Medoxomil IP — 40 mg

Cilnidipine IP — 10 mg

Excipients — q.s.

Colour: Approved colour used

Dosage form: Oral tablet

Product Description

OLMEROOT-CL 40 is a scientifically balanced antihypertensive combination of Olmesartan Medoxomil 40 mg and Cilnidipine 10 mg, formulated for the effective management of hypertension and long-term cardiovascular and renal protection. This combination provides dual blood pressure control by combining the renin-angiotensin system blockade of Olmesartan with the advanced dual calcium channel blocking action of Cilnidipine, resulting in superior antihypertensive efficacy and enhanced target organ protection.

Olmesartan Medoxomil is a potent angiotensin II receptor blocker (ARB) that promotes vasodilation, reduces peripheral vascular resistance, and provides cardiovascular and renal protection. Cilnidipine is a unique dual L-type and N-type calcium channel blocker that reduces peripheral vascular resistance, suppresses sympathetic overactivity, improves renal hemodynamics, and minimizes reflex tachycardia.

OLMEROOT-CL 40 is particularly beneficial in patients with uncontrolled hypertension, hypertension associated with diabetes, chronic kidney disease, proteinuria, metabolic syndrome, elderly hypertension, and patients requiring intensive combination antihypertensive therapy.

Technical Knowledge of Olmesartan Medoxomil and Cilnidipine

Olmesartan Medoxomil is a prodrug that is converted to Olmesartan, which selectively blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction, aldosterone secretion, sympathetic activation, and vascular remodeling.

Cilnidipine blocks both L-type calcium channels in vascular smooth muscle and N-type calcium channels in sympathetic nerve terminals. This dual mechanism reduces arterial vasoconstriction while decreasing sympathetic neurotransmitter release, resulting in sustained blood pressure reduction, improved renal perfusion, and reduced glomerular hypertension.

The combination of Olmesartan and Cilnidipine provides complementary antihypertensive mechanisms with additional cardiovascular and nephroprotective benefits.

Mechanism of Action

Olmesartan blocks AT1 receptors, promotes vasodilation, reduces peripheral vascular resistance, decreases aldosterone secretion, improves vascular function, and protects cardiovascular and renal tissues.

Cilnidipine blocks L-type and N-type calcium channels, relaxes vascular smooth muscle, suppresses sympathetic activity, improves renal blood flow, reduces glomerular pressure, and provides sustained antihypertensive action.

Key Benefits

Effective reduction of systolic and diastolic blood pressure

Dual antihypertensive mechanism

Provides sustained 24-hour blood pressure control

Supports cardiovascular and renal protection

Reduces sympathetic overactivity

Improves renal hemodynamics

Helps reduce proteinuria in diabetic and renal patients

Minimizes reflex tachycardia

Suitable for long-term hypertension management under medical supervision

Clinical Applications

OLMEROOT-CL 40 is commonly prescribed for essential hypertension, uncontrolled hypertension requiring combination therapy, hypertension with diabetes mellitus, hypertension with chronic kidney disease, hypertension with proteinuria, metabolic syndrome, elderly hypertension, and long-term cardiovascular and renal risk reduction.

Facts About Olmesartan Medoxomil and Cilnidipine

Olmesartan is a highly selective ARB with excellent antihypertensive efficacy and proven cardiovascular and renal protective benefits. Cilnidipine is an advanced calcium channel blocker with dual L-type and N-type channel blocking properties, providing effective blood pressure control with favorable renal and sympathetic modulation effects. The combination is widely used for patients requiring intensive blood pressure control and enhanced nephroprotection.

Key Facts

ARB and dual calcium channel blocker combination therapy

Olmesartan Medoxomil 40 mg for vascular and renal protection

Cilnidipine 10 mg for advanced blood pressure and renal control

Provides sustained 24-hour antihypertensive action

Effective in hypertension with diabetes and chronic kidney disease

Evidence-based cardiovascular and nephroprotective combination therapy

Quality-assured pharmaceutical formulation

PCD Pharma Franchise Opportunity

OLMEROOT-CL 40 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, Nephrology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, chronic kidney disease, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this combination.

Why Choose OLMEROOT-CL 40 for PCD Pharma Franchise?

High prescription potential

Strong physician and cardiologist acceptance

Attractive monopoly franchise opportunity

Competitive pricing

Promotional support available

Visual aids and marketing inputs

Consistent product quality

Excellent repeat business potential

Third Party Manufacturing

Chemsroot Pharmaceutical offers Third Party Manufacturing of Olmesartan Medoxomil 40 mg and Cilnidipine 10 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.

Our Third Party Manufacturing Services Include

Private label manufacturing

Contract manufacturing

Custom brand manufacturing

Loan license manufacturing

DCGI-compliant production

GMP-certified manufacturing

Batch manufacturing documentation

Product registration support

Customized packaging and artwork

Monopoly franchise packaging

Bulk manufacturing capability

Manufacturing Features

Pharmaceutical-grade raw materials

IP/BP/USP quality standards

In-process quality control

Finished product testing

Stability-oriented formulation

Moisture-controlled tablet manufacturing

Blister and Alu-Alu packaging options

OLMEROOT-CL 40 from DIABGLYM combines effective blood pressure control, comprehensive cardiovascular and renal protection, evidence-based combination therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Olmesartan and Cilnidipine formulation.